Clinical Trial Update: A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy [Phase 2]

View source ↗

Summary

This document reports a Phase 2 clinical trial evaluating ARGX-119 administered intravenously in children aged 5 to under 18 with Spinal Muscular Atrophy, focus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• ARGX-119

Snippet

Sponsor: argenx | Conditions: Spinal Muscular Atrophy (SMA) | Phase 2 | Status: RECRUITING